Table 1 Expression and outcomes of the JAK–STAT pathway in digestive tract tumors
Cancer | Expression in cancers | Outcomes of the activated JAK-STAT pathway in cancers | Year | Refs |
|---|---|---|---|---|
Liver cancer | upregulation of JAK1, JAK2, JAK3, and STAT3 | enhanced immunosuppression, and tumor metastasis | 2023 | [136] |
Liver cancer | upregulation of JAK2, and STAT3 | enhanced cell proliferation, clone formation, invasion, and migration | 2021 | [169] |
Liver cancer | upregulation of JAK1, JAK2, TYK2, STAT1, STAT3, and STAT5 | enhanced cell anti-apoptosis | 2006 | [129] |
Liver cancer | upregulation of JAK1, JAK2, STAT1, and STAT3 | enhanced cell proliferation | 2008 | [168] |
Liver cancer | upregulation of STAT3 | enhanced cell migration, and invasion | 2018 | [157] |
Liver cancer | upregulation of STAT3 | enhanced cell proliferation | 2007 | [156] |
Liver cancer | upregulation of STAT3 | enhanced cell migration | 2017 | [158] |
Liver cancer | upregulation of STAT3 | enhanced cell proliferation, migration, invasion, and tumorigenicity | 2018 | [170] |
Liver cancer | upregulation of STAT3 | enhanced tumor formation, and drug resistance | 2020 | [171] |
liver cancer | downregulation of STAT1 | enhanced cell growth arrest, and the responsiveness to IFN-α | 2018 | [162] |
Liver cancer | downregulation of STAT5 | enhanced hepatoprotective functions | 2012 | [149] |
Gastric cancer | upregulation of JAK1, JAK2, and STAT1 | enhanced cell proliferation and repression | 2022 | [190] |
Gastric cancer | upregulation of STAT3 | enhanced cell proliferation and anti-apoptosis | 2012 | [177] |
Gastric cancer | upregulation of STAT3 | enhanced dysplastic lesions and loss of mucosal integrity | 2019 | [181] |
Gastric cancer | upregulation of STAT3 | enhanced the immunosuppression of FasL + PD-L2 + neutrophils, and tumor growth | 2022 | [194] |
Gastric cancer | upregulation of STAT3 | enhanced the immunosuppression of PD-L1 + neutrophils, and tumor growth | 2017 | [195] |
Gastric cancer | upregulation of STAT1 | enhanced inflammatory immune response | 2020 | [201] |
Gastric cancer | upregulation of STAT1 | enhanced the polarization of M2-type macrophage | 2022 | [185] |
Gastric cancer | upregulation of STAT1, and STAT3 | enhanced inflammation, and immune evasion | 2018 | [200] |
Gastric cancer | upregulation of STAT1, and STAT3 | enhanced immunosuppression, and anti-apoptosis | 2020 | [186] |
Colorectal cancer | upregulation of JAK2, and STAT3 | enhanced cell migration and proliferation | 2021 | [36] |
Colorectal cancer | upregulation of STAT3 | enhanced cell proliferation, and adenoma formation | 2022 | [212] |
Colorectal cancer | upregulation of STAT3 | enhanced cell invasion | 2018 | [211] |
Colorectal cancer | upregulation of STAT3 | enhanced cell proliferation, and metastasis | 2018 | [213] |
Colorectal cancer | upregulation of STAT3 | enhanced cell growth, migration, and invasion | 2018 | [217] |
Colorectal cancer | upregulation of STAT3 | enhanced cell proliferation | 2018 | [218] |
Pancreatic cancer | upregulation of STAT3 | enhanced chemotherapy resistance | 2023 | [223] |
Pancreatic cancer | upregulation of STAT3 | enhanced acinar-to-ductal metaplasia | 2016 | [227] |
Pancreatic cancer | upregulation of STAT3 | enhanced acinar to ductal metaplasia, stem cell features, and the epithelial-mesenchymal transition | 2020 | [228] |
Pancreatic cancer | upregulation of STAT3 | enhanced tumor growth inhibition, and inhibited autophagic death | 2012 | [235] |
Esophageal cancer | upregulation of JAK1, JAK2, STAT1, and STAT3 | enhanced cell migration | 2004 | [245] |
Esophageal cancer | upregulation of STAT3 | enhanced tumor survival, and proliferation | 2012 | [244] |
Esophageal cancer | upregulation of STAT3 | enhanced 5-FU resistance | 2023 | [247] |
Esophageal cancer | upregulation of STAT1 | enhanced tumor growth, and invasion | 2019 | [246] |